CY2168B1 - Fusion proteins their preparation and use - Google Patents

Fusion proteins their preparation and use

Info

Publication number
CY2168B1
CY2168B1 CY0000013A CY0000013A CY2168B1 CY 2168 B1 CY2168 B1 CY 2168B1 CY 0000013 A CY0000013 A CY 0000013A CY 0000013 A CY0000013 A CY 0000013A CY 2168 B1 CY2168 B1 CY 2168B1
Authority
CY
Cyprus
Prior art keywords
fusion proteins
manner
preparation
fusion protein
oligonucleotide
Prior art date
Application number
CY0000013A
Other languages
English (en)
Inventor
Siegfried Stengelin
Wolfgang Ulmer
Paul Habermann
Eugen Uhlmann
Brian Seed
Original Assignee
Gen Hospital Corp
Aventis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp, Aventis Pharma Gmbh filed Critical Gen Hospital Corp
Publication of CY2168B1 publication Critical patent/CY2168B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CY0000013A 1989-08-29 2000-05-03 Fusion proteins their preparation and use CY2168B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39987489A 1989-08-29 1989-08-29

Publications (1)

Publication Number Publication Date
CY2168B1 true CY2168B1 (en) 2002-08-23

Family

ID=23581315

Family Applications (1)

Application Number Title Priority Date Filing Date
CY0000013A CY2168B1 (en) 1989-08-29 2000-05-03 Fusion proteins their preparation and use

Country Status (19)

Country Link
EP (1) EP0489780B1 (fr)
JP (1) JP3043803B2 (fr)
KR (1) KR0159786B1 (fr)
AT (1) ATE173018T1 (fr)
AU (1) AU638277B2 (fr)
CA (1) CA2065146C (fr)
CY (1) CY2168B1 (fr)
DE (1) DE69032743T2 (fr)
DK (1) DK0489780T3 (fr)
ES (1) ES2124216T3 (fr)
FI (1) FI113183B (fr)
GR (1) GR1005153B (fr)
HU (1) HU216069B (fr)
IE (1) IE903120A1 (fr)
IL (1) IL95495A (fr)
NO (1) NO308667B1 (fr)
PT (1) PT95111B (fr)
WO (1) WO1991003550A1 (fr)
ZA (1) ZA906839B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5426036A (en) * 1987-05-05 1995-06-20 Hoechst Aktiengesellschaft Processes for the preparation of foreign proteins in streptomycetes
DK0600372T3 (da) * 1992-12-02 1997-08-11 Hoechst Ag Fremgangsmåde til fremstilling af proinsulin med korrekt forbundne cystinbroer.
DK0622376T3 (da) * 1993-04-27 2001-11-12 Hoechst Ag Amorfe monosfæriske former af insulinderivater
WO1995009914A1 (fr) * 1993-10-05 1995-04-13 Asahi Glass Company Ltd. Vecteur de multiclonage, vecteur d'expression, et production d'une proteine exogene au moyen dudit vecteur d'expression
US6001604A (en) * 1993-12-29 1999-12-14 Bio-Technology General Corp. Refolding of proinsulins without addition of reducing agents
DE4405179A1 (de) * 1994-02-18 1995-08-24 Hoechst Ag Verfahren zur Gewinnung von Insulin mit korrekt verbundenen Cystinbrücken
US5683987A (en) * 1994-07-12 1997-11-04 The Board Of Regents Of The University Of Nebraska Therapeutic oligonucleotides targeting the human MDR1 and MRP genes
DK0821006T3 (da) 1996-07-26 2004-08-16 Aventis Pharma Gmbh Insulinderivater med öget zinkbinding
DE19735711C2 (de) 1997-08-18 2001-04-26 Aventis Pharma Gmbh Verfahren zur Herstellung eines Vorläufers von Insulin oder Insulinderivaten mit korrekt verbundenen Cystinbrücken
DE19825447A1 (de) 1998-06-06 1999-12-09 Hoechst Marion Roussel De Gmbh Neue Insulinanaloga mit erhöhter Zinkbildung
DE19915938A1 (de) 1999-04-09 2000-10-19 Aventis Pharma Gmbh Herstellung von pankreatischer Procarboxypeptidase B, Isoformen und Muteinen davon und ihre Verwendung
DE19930676B4 (de) 1999-07-02 2006-01-19 Sanofi-Aventis Deutschland Gmbh Verfahren zur Stabilisierung von Insulin, Insulinderivaten und/oder deren Vorläufer in komplexen Mischungen bei deren Lagerung in wäßrigen Lösungsmitteln
US7202059B2 (en) 2001-02-20 2007-04-10 Sanofi-Aventis Deutschland Gmbh Fusion proteins capable of being secreted into a fermentation medium
US7638618B2 (en) 2001-02-20 2009-12-29 Sanofi-Aventis Deutschland Gmbh Nucleic acids encoding a hirudin and pro-insulin as superscretable peptides and for parallel improvement of the exported forms of one or more polypeptides of interest
DE10235168A1 (de) 2002-08-01 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Reinigung von Preproinsulin
US20060035316A1 (en) * 2002-11-12 2006-02-16 Sang-Yong Lee Plasmids expressing human insulin and the preparation method for human insuling thereby
DE102008025007A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN102007143B (zh) 2008-01-09 2015-08-26 塞诺菲-安万特德国有限公司 具有超延迟时效特征的新型胰岛素衍生物
DE102008003568A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
DE102008003566A1 (de) 2008-01-09 2009-07-16 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
EP2229406B1 (fr) 2008-01-09 2015-04-22 Sanofi-Aventis Deutschland GmbH Nouveaux dérivés d'insuline à profil temporel/d'action extrêmement retardé
DE102008025008A1 (de) 2008-05-24 2009-11-26 Sanofi-Aventis Deutschland Gmbh Neue Insulinderivate mit extrem verzögertem Zeit-/ Wirkungsprofil
CN102256618A (zh) 2008-10-17 2011-11-23 赛诺菲-安万特德国有限公司 胰岛素和glp-1激动剂的组合
PL2451437T3 (pl) 2009-07-06 2017-05-31 Sanofi-Aventis Deutschland Gmbh Wodne preparaty insuliny zawierające metioninę
TR201809460T4 (tr) 2009-11-13 2018-07-23 Sanofi Aventis Deutschland Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim.
NZ599847A (en) 2009-11-13 2013-09-27 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
WO2012028172A1 (fr) 2010-08-30 2012-03-08 Sanofi-Aventis Deutschland Gmbh Utilisation de lixisenatide pour fabrication de médicament pour traitement du diabète sucré de type 2
DK2739646T3 (en) 2011-05-10 2018-02-26 Stefan Hermann COMPREHENSIVE BUFFER SYSTEM FOR RENATURING HUMAN PROINSULIN OR PROINSULIN DERIVATIVES
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
AR087693A1 (es) 2011-08-29 2014-04-09 Sanofi Aventis Deutschland Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
JP5858945B2 (ja) 2012-03-15 2016-02-10 アークレイ株式会社 酵素を用いた測定方法
PE20171622A1 (es) 2014-12-12 2017-11-02 Sanofi Aventis Deutschland Formulacion de relacion fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
JP6976254B2 (ja) * 2015-09-18 2021-12-08 バイオネット ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツングBioNet Pharma GmbH Ｃｄ−ｒａｐ前駆体タンパク質の使用による、ｃｄ−ｒａｐの製造方法における発現およびフォールディングの改善
JP7460182B2 (ja) * 2019-02-19 2024-04-02 ザ、トラスティーズ オブ プリンストン ユニバーシティ フォールディングされたドメインおよびｒｎａ顆粒会合タンパク質ドメインの光制御オリゴマー化および相分離のためのシステムおよび方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4366246A (en) * 1977-11-08 1982-12-28 Genentech, Inc. Method for microbial polypeptide expression
US4431739A (en) * 1979-11-05 1984-02-14 Genentech, Inc. Transformant bacterial culture capable of expressing heterologous protein
US4769326A (en) * 1980-02-29 1988-09-06 The Regents Of The University Of California Expression linkers
US4652639A (en) * 1982-05-06 1987-03-24 Amgen Manufacture and expression of structural genes
EP0195680A3 (fr) * 1985-03-21 1987-06-10 Immunex Corporation Synthèse de protéines avec un peptide d'identification
DE3526995A1 (de) * 1985-07-27 1987-02-05 Hoechst Ag Fusionsproteine, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
NO308667B1 (no) 2000-10-09
FI113183B (fi) 2004-03-15
JPH05501799A (ja) 1993-04-08
FI920923A0 (fi) 1992-02-28
DK0489780T3 (da) 1999-07-19
GR900100635A (el) 1991-12-30
GR1005153B (el) 2006-03-13
AU6287290A (en) 1991-04-08
ZA906839B (en) 1991-06-26
DE69032743D1 (de) 1998-12-10
AU638277B2 (en) 1993-06-24
JP3043803B2 (ja) 2000-05-22
PT95111A (pt) 1991-05-22
EP0489780B1 (fr) 1998-11-04
ES2124216T3 (es) 1999-02-01
HU216069B (hu) 1999-04-28
WO1991003550A1 (fr) 1991-03-21
HK1012026A1 (en) 1999-07-23
DE69032743T2 (de) 1999-06-17
EP0489780A1 (fr) 1992-06-17
EP0489780A4 (en) 1992-08-12
HUT60327A (en) 1992-08-28
KR0159786B1 (ko) 1998-11-16
IE903120A1 (en) 1991-03-13
HU9200674D0 (en) 1992-08-28
PT95111B (pt) 1998-10-30
ATE173018T1 (de) 1998-11-15
IL95495A0 (en) 1991-06-30
CA2065146C (fr) 2002-07-23
NO920774D0 (no) 1992-02-27
CA2065146A1 (fr) 1991-03-01
NO920774L (no) 1992-04-28
IL95495A (en) 1996-10-16

Similar Documents

Publication Publication Date Title
CY2168B1 (en) Fusion proteins their preparation and use
ATE88501T1 (de) Rekombinante dns-expressionsvektoren.
AU6569386A (en) Eukaryotic fusion proteins, the preparation and use thereof and means for carrying out the process
RU93045577A (ru) Слитные полипептиды
ATE46536T1 (de) Verfahren zur herstellung von reifen proteinen in wirtzellen von wirbeltieren.
AU3461797A (en) Fas ligand-like protein, its production and use
IL173399A0 (en) Circular dna molecule with conditional origin of replication which contains nucleic acid of interest and selection marker but does not encode its replication initiation protein, method for preparing the same and use thereof in gene therapy
IL74972A (en) Atrial natriuretic/vasodilator polypeptides and process for the preparation thereof
HUT46061A (en) Dna sequences encoding hirudin-like protein and process for producing such proteins
NZ233450A (en) Cdna sequence encoding lactoferrin and its use in production of lactoferrin
ES8506347A1 (es) Un metodo para producir un polipeptido de tipo il-2-".
ATE419357T1 (de) Dna 19355 polypeptide, ein homolog des tumornekrosefaktors
NZ292565A (en) Production of stabilised complement protein-3 convertase
ES8604309A1 (es) Un procedimiento para obtener un adn que codifica un factor de necrosis de tumor de conejo
EP0395706A4 (en) Production of gonorrheal pi proteins and vaccines
DE3377917D1 (en) Dna fragments encoding for an immunogenic peptide capable of inducing in vivo synthesis of anti-polio virus antibodies
ZA9610456B (en) N-terminally extended proteins expressed in yeast
ES553374A0 (es) Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.
JPS6474989A (en) Dna to code human lysozyme
GR3036312T3 (en) Polypeptides and dna encoding same, associated with human malaria parasites.
DK171489A (da) Peptidderivater
IT1243286B (it) Processo per isolamento ed espressione del fattore neuronotrofico ciliare umano mediante la tecnologia del dna ricombinante.
JPS6474988A (en) Synthetic gene of cystatin c, corresponding recombinant plasmid and recombinant
MX9707244A (es) Expresion de genes en celulas de mamifero.